Constant Pharmaceuticals LLC, a privately held US based biopharmaceutical company focused on the treatment of stroke rec...
Japanese pharma giant Takeda has announced plans to invest €25 million in the construction of a new facility at&nbs...
Singapore – Takeda Pharmaceuticals has announced the establishment of the centre of Excellence in Singapore for va...
Roche and Takeda have announced that they will be using organ-chip technology in their R&D Programs through partners...
Valeant Pharmaceuticals International’s subsidiary has entered into an exclusive license agreement with Kaken Phar...
Japan's pioneer genetic testing and research company, Genesis Healthcare Co. has completed a third-party equity allocati...
Japan’s Shionogi has announced that the New Drug Application (NDA) for lusutrombopag (S-888711) -an investigationa...
Japan based Sumitomo Dainippon Pharma Co., Ltd. has announced the appointment of Hiroshi Nomura as Representative Direct...
Singapore- MEDICAL JAPAN 2018, one of the largest and most comprehensive trade show successfully concluded its fourth ed...
Daiichi Sankyo has has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour ...
Takeda Pharmaceutical Company Limited has announced that it has entered into a research, development and commercial coll...
A group of researchers, at the University of Tokyo’s Graduate School of Engineering in collaboration with Dai Nipp...
A group of researchers from Osaka University, Japan has developed a sensing method with the potential to significantly c...
Iran’s Ministry of Health and the Japan International Cooperation Agency (JICA) have signed a Memorandum of Unders...
A team of scientists at Nagoya University, Japan has introduced substituted warped nanographene, which is soluble i...
Researchers from Shinshu University have found that, unlike conventional plates, the titanium fiber plates do not cause ...
Singapore – Takeda has started a new initiative aimed at helping inflammatory bowel disease patients sort thr...
YL Biologics (YLB), a joint venture by drugmaker Lupin and Yoshindo, has successfully completed the late phase clinical ...
